WallStSmart

BioCryst Pharmaceuticals Inc (BCRX)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 1859% more annual revenue ($17.35B vs $885.72M). TEVA leads profitability with a 9.0% profit margin vs -51.7%. TEVA appears more attractively valued with a PEG of 0.85. TEVA earns a higher WallStSmart Score of 66/100 (B-).

BCRX

Avoid

31

out of 100

Grade: F

Growth: 6.7Profit: 4.0Value: 4.0Quality: 6.0
Piotroski: 5/9Altman Z: 0.31

TEVA

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 6.3Quality: 4.0
Piotroski: 6/9Altman Z: 0.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BCRX1 strengths · Avg: 10.0/10
Debt/EquityHealth
-1.5510/10

Conservative balance sheet, low leverage

TEVA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation
0.858/10

Growing faster than its price suggests

Areas to Watch

BCRX4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

PEG RatioValuation
9.392/10

Expensive relative to growth rate

Return on EquityProfitability
-1925.0%2/10

ROE of -1925.0% — below average capital efficiency

Free Cash FlowQuality
$-62.54M2/10

Negative free cash flow — burning cash

TEVA4 concerns · Avg: 3.0/10
P/E RatioValuation
25.8x4/10

Moderate valuation

Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Free Cash FlowQuality
$-208.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BCRX

The strongest argument for BCRX centers on Debt/Equity.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.

Bear Case : BCRX

The primary concerns for BCRX are EPS Growth, PEG Ratio, Return on Equity.

Bear Case : TEVA

The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.

Key Dynamics to Monitor

BCRX profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.

TEVA carries more volatility with a beta of 0.85 — expect wider price swings.

BCRX is growing revenue faster at 7.5% — sustainability is the question.

BCRX generates stronger free cash flow (-63M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (66/100 vs 31/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BioCryst Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.

Visit Website →

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?